SELLAS surges on late-stage trial win for cancer vaccine

SELLAS Life Sciences (SLS) shares rose over 200% premarket after reporting success in a late-stage trial for its cancer vaccine, galinpepimut-S, in acute myeloid leukemia patients, based on topline data.

Original reporting
Published Nov 17, 2026, 1:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SELLAS surges on late-stage trial win for cancer vaccine — source image
Decision brief

The 30-second read

$SLSBullishMed
01

Why it matters

A late-stage trial success claim is a major de-risking event that can change valuation expectations quickly, especially for pre-commercial biotech names.

02

Market read

The article links a very large premarket jump to a specific late-stage clinical catalyst, making it actionable for biotech momentum and event-driven positioning.

03

What to watch

Traders may overreact to headline success without knowing primary endpoint achievement, statistical strength, comparator context, and next-step regulatory/timeline implications.

Relevance 8/10Novelty 8/10Timing: premarket today, immediately after topline late-stage trial success news

Background

The company is developing an immunotherapeutic cancer vaccine, galinpepimut-S (GPS), for acute myeloid leukemia.

Company-level read

Ticker impact

$SLSBullishMedium confidence
Context

SELLAS shares surged more than 200% premarket after reporting late-stage trial success for its acute myeloid leukemia cancer vaccine galinpepimut-S.

Expected impact

Likely upward pressure as traders price in improved odds of further development and potential regulatory path.

Evidence & confidence

The article attributes a large same-session premarket move directly to late-stage trial topline success, which is a high-signal catalyst for biotech risk/reward.

Market effects

Supports sentiment for immuno-oncology and AML vaccine approaches, potentially lifting peer attention to late-stage readouts.

Limited, primarily US small/mid-cap biotech trading flows.

Low, unless follow-on details (endpoints, durability, safety) later broaden interest beyond the US.

Counterpoint

Topline “succeeded” language may still mask endpoint specifics, durability, and safety signals; the stock can retrace if details disappoint.

Key entities

  • SELLAS Life Sciences

    Subject of the article; reported late-stage trial success for galinpepimut-S in acute myeloid leukemia.

  • Galinpepimut-S (GPS)

    SELLAS immunotherapeutic cancer vaccine referenced as succeeding in late-stage patients.

  • Acute myeloid leukemia

    Disease area where the trial success was reported.

Related articles

$SLSHighAI 9/10

Why is Sellas Life Sciences stock surging today?

Sellas Life Sciences (SLS) stock surged 245.1% in pre-market trading after its Phase 3 REGAL trial of galinpepimut-S met its primary endpoint, showing a 41% reduction in death risk. The company plans to engage with the FDA for an accelerated filing strategy. The stock was halted before resuming higher.

$SLSHighAI 9/10

SELLAS Life Sciences stock soars 240% on positive cancer trial

SELLAS Life Sciences (NASDAQ:SLS) shares rose 240% after reporting positive Phase 3 trial results for its cancer vaccine, GPS. The trial met its primary endpoint, showing a 41% reduction in death risk and improved median survival. The company plans to discuss an accelerated FDA filing strategy. GPS was well-tolerated with mild to moderate side effects.

$SLSHighAI 9/10

Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027

Sellas Life Sciences (SLS) reported that its experimental cancer vaccine, GPS, met its primary goal in a Phase 3 trial, reducing the risk of death by 41% in AML patients. The trial showed a median overall survival of 24 months vs. 14.7 months for the control group. The company plans to file for FDA approval in the first half of 2027. SLS shares rose 7.1% pre-market before trading was halted.

$SLSMedAI 8/10

Sellas' Cancer Vaccine Cuts Death Risk By 41% In Phase 3 Leukemia Trial

SELLAS Life Sciences (SLS) reported that its cancer vaccine, galinpepimut-S, met the primary survival endpoint in a Phase 3 trial for acute myeloid leukemia. The vaccine reduced death risk by 41% compared to standard treatment, with median survival of 24 months versus 14.7 months. The company plans to discuss FDA filing strategy in 2027. SLS shares rose 7.10% in pre-market trading.

$SLSHighAI 9/10

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Ov

SELLAS Life Sciences (NASDAQ: SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, GPS, showing a 41% reduction in death risk and median OS of 24.0 months vs. 14.7 months for standard treatment. The company plans to meet with the FDA to discuss regulatory path. GPS was well-tolerated with no new safety signals. SELLAS will host a webcast to discuss results and next steps.

$SLSMedAI 8/10

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a…

SELLAS Life Sciences Group, Inc. (SLS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid